Share this article on:

Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft

Antonini, Teresa M.a,b,c,k; Furlan, Valeried,k; Teicher, Elinaa,e,k; Haim-Boukobza, Stephanieb,c,f,k; Sebagh, Myleneb,c,g,k; Coilly, Audreya,b,c,k; Bonhomme-Faivre, Laurenceh,k; Peytavin, Gillesi,j; Roque-Afonso, Anne-Marieb,c,f,k; Vittecoq, Daniele,k; Samuel, Didiera,b,c,k; Taburet, Anne-Maried,k; Duclos-Vallée, Jean-Charlesa,b,c,k

doi: 10.1097/01.aids.0000432539.77711.f4
Research Letters

We report, for the first time, the outcome of anti-hepatitis C virus (HCV) triple therapy with telaprevir in an HIV/HCV co-infected transplanted patient. After liver transplantation, the patient experienced a severe HCV recurrence with fibrosing cholestatic hepatitis, and anti-HCV therapy with pegylated interferon alpha 2a, ribavirin and telaprevir was initiated. A sustained virological response was achieved after 48 weeks of anti-HCV therapy. Drug–drug interactions between antiretroviral therapy, immunosuppressive agents and anti-HCV therapy could be managed.

aAP-HP, Hôpital Paul Brousse, Centre Hépato-Biliaire

bUniversity Paris-Sud, UMR-S 785

cInserm, Unité 785, Villejuif

dAP-HP, HôpitalBicêtre, Pharmacie Clinique

eAP-HP, Hôpital Bicêtre, Service de Médecine Interne, Immunologie et Maladies Infectieuses, Le Kremlin Bicêtre

fAP-HP Hôpital Paul Brousse, Service de Virologie

gAP-HP, Hôpital Paul Brousse, Service Anatomie Pathologique

hAP-HP, Hôpital Paul Brousse, Pharmacie Clinique, Villejuif

iAP-HP, GH Xavier Bichat-Claude Bernard, Laboratoire de Toxicologie et Pharmacocinétique

jUniversité Paris, Paris

kHepatinov, Villejuif, France.

Correspondence to Professor Jean-Charles Duclos-Vallee, MD, PhD, Centre Hépato-Biliaire, Hôpital Paul Brousse, 12, avenue Paul Vaillant Couturier, 94800 Villejuif, France. Tel: +33 1 45 59 30 42; fax: +33 1 45 59 38 57; e-mail:

© 2013 Lippincott Williams & Wilkins, Inc.